Please use this identifier to cite or link to this item: https://doi.org/10.1080/14712598.2018.1448382
Title: Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations
Authors: Tan, Warren KY
Purnamawati, Kristy
Pakkiri, Leroy S
Tan, Sock Hwee 
Yang, Xiaoxun
Chan, Mark Y
Drum, Chester L
Keywords: Science & Technology
Life Sciences & Biomedicine
Biotechnology & Applied Microbiology
Medicine, Research & Experimental
Research & Experimental Medicine
Thymosin beta-4
plasma
serum
biomarker
platelets
HUMAN BLOOD-PLATELETS
RHEUMATOID-ARTHRITIS
PLASMA
SERUM
PEPTIDES
BETA(4)
CENTRIFUGATION
ACTIVATION
THERAPY
Issue Date: 1-Jan-2018
Publisher: TAYLOR & FRANCIS LTD
Citation: Tan, Warren KY, Purnamawati, Kristy, Pakkiri, Leroy S, Tan, Sock Hwee, Yang, Xiaoxun, Chan, Mark Y, Drum, Chester L (2018-01-01). Sources of variability in quantifying circulating thymosin beta-4: literature review and recommendations. EXPERT OPINION ON BIOLOGICAL THERAPY 18 (sup1) : 141-147. ScholarBank@NUS Repository. https://doi.org/10.1080/14712598.2018.1448382
Abstract: Introduction: Thymosin beta-4 (TB4) is an endogenous peptide with protective and regenerative effects in models of cellular and organ injury. TB4 is increasingly measured as a potential plasma or serum biomarker in human cardiovascular, liver, infectious, and autoimmune disease. Areas covered: The focus of this review is the quantification of TB4 in clinical cohort studies and whether reported TB4 concentrations differ with respect to method of sample preparation. We survey current literature for studies measuring TB4 in human serum or plasma and compare reported concentrations in healthy controls. Expert opinion: We find substantial intra- and inter- study variability in healthy controls, and a lack of protocol standardization. We further highlight three factors that may confound TB4 clinical measurements and should be considered in future study design: 1) residual platelets remaining in suspension after centrifugation, 2) TB4 release following ex vivo platelet activation, and 3) specificity of assays towards posttranslational modifications. Accordingly, we put forth our recommendations to minimize residual and activated platelets during sample collection, and to cross-validate TB4 measurements using both antibody-based and mass spectrometry-based methods.
Source Title: EXPERT OPINION ON BIOLOGICAL THERAPY
URI: https://scholarbank.nus.edu.sg/handle/10635/206024
ISSN: 14712598
17447682
DOI: 10.1080/14712598.2018.1448382
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Sources of variability in quantifying circulating thymosin beta 4 literature review and recommendations.pdfPublished version1.72 MBAdobe PDF

CLOSED

None

SCOPUSTM   
Citations

6
checked on May 14, 2022

Page view(s)

46
checked on May 12, 2022

Download(s)

1
checked on May 12, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.